EVEREN-LIMITED
Everen Limited (Everen) convened its March 2024 Board Meeting on Tuesday, March 19th followed by its Annual General Meeting (AGM) on Thursday, March 21st.
During the Board Meeting, the directors approved Everen’s 2023 financial statements and discussed the ongoing execution of the 5-year Strategic Plan. Additionally, the Board declared a dividend of $350 million, affirming Everen’s commitment to delivering value to its shareholders. This dividend is payable on or before September 30, 2024 to shareholders of record on March 19, 2024. The Board also thanked retiring directors Gwenola Jan, Michele Waters, and Robert Wondolleck for their years of service.
At the AGM, shareholders voted to approve amendments to Everen’s Bye-Laws and Shareholders’ Agreement, aimed at enhancing governance and operational flexibility. Shareholders also elected a new Board of Directors who will serve until the March 2025 AGM.
During the AGM, Bertil Olsson, President and Chief Executive Officer announced that he will be retiring in March of 2025 and noted “The Company is conducting an extensive recruitment process to source my successor. Whilst my retirement is still a year away, I would like to express what an honor and privilege it has been to lead this amazing organization over the past 8.5 years. It has truly been the highlight of my career. I am looking forward to the continued work over the coming year with our very talented team and Board of Directors and to transition the business to the next leader upon completion of the succession recruitment process.”
Following Mr. Olsson’s announcement, John Weisner, Chair of the Everen Board expressed the Board’s appreciation for Mr. Olsson’s sound stewardship and highlighted several key accomplishments during his tenure as CEO.
Subsequent to the AGM, the newly elected Board convened and appointed John Weisner as Chair of the Board and Brian Mullen as Deputy Chair for 2024.
For the fiscal year 2023, Everen reported a net income of $679.5 million, driven by a rebound in the investment portfolio, positive underwriting income and effective cost management. Mr. Olsson attributed this success to Everen’s unwavering commitment to creating long-term value and enhancing its value proposition. He highlighted Everen’s track record of returning over $3.1 billion in dividends to shareholders over the past decade.
Robert Foskey, Senior Vice President and Chief Operating Officer commented, “In 2023, Everen performed very well and remained dedicated to advancing Strategic Plan initiatives including our marketing and communication activities and facilitating the use of our coverages through the approval of the use of Incorporated Cell Captives. The addition of three new members underscores our continued growth, geographic and insured portfolio diversification, and the strong interest from global energy companies to be a part of our world-class energy insurance mutual.”
About Everen Limited:
Headquartered in Bermuda, Everen Limited is the insurer of choice for the world’s leading energy companies, insuring over $4 trillion of global energy assets. The company was established in 1972 as a mutual insurer, an innovative structure whereby its policyholders are also its shareholders and coverage is provided at cost. Everen offers its shareholders per occurrence property limits of up to $450 million across an extensive range of energy industry assets – from traditional oil and gas through to alternative industry segments such as renewables. Everen’s shareholders consist of medium to large sized energy companies in both the public and private sectors with an investment grade rating or equivalent. Everen is rated A by S&P and A2 by Moody’s.
For further information about the company, please visit www.everen.bm
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325711236/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 14:00:00 CET | Press release
An Alliance to Combat Resistance: Debiopharm and NetTargets will collaborate to develop next-generation, dual-payload Antibody-Drug Conjugates (ADCs) designed to overcome acquired resistance mechanisms in difficult-to-treat cancers. AI-Powered Precision: The collaboration combines NetTargets' proprietary AI discovery platform—to identify synergistic drug pairings—with Debiopharm’s MLINK Duo technology for coordinated delivery of two distinct warheads on a single ADC. Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This allianc
Bending Spoons Raises $710M for Continued Investment and Growth30.10.2025 14:00:00 CET | Press release
Bending Spoons, one of Europe’s leading technology companies, today announced it has raised $710 million in equity at a pre-money valuation of $11 billion. The round was led by accounts advised by T. Rowe Price Investment Management, Inc., with participation from Baillie Gifford, Cox Enterprises, Durable Capital Partners, Fidelity Management & Research Company, Foxhaven Asset Management, and Radcliff, among others. Goldman Sachs International acted as sole placement agent and Clifford Chance served as legal advisor to the transaction. Notarial advisory services were provided by ZNR Notai. “This moment is a validation of a decade’s worth of work and it serves as an important recognition of what we’ve accomplished at Bending Spoons so far. We remain early in our journey and have ambitious plans for continued investment and growth,” shares Luca Ferrari, co-founder and CEO of Bending Spoons. “We’re proud to bring on some of the world’s finest investors who believe in our approach to value
Owlet® Strengthens Market Leadership as Dream Sight™ Becomes the First Baby Monitor Awarded the SGS Cybersecurity Mark30.10.2025 13:45:00 CET | Press release
Earning the first-ever SGS Cybersecurity Mark in the baby monitor category, Owlet reinforces its leadership in safety, security, privacy, and innovation. Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced that its newest video monitoring device, Dream Sight, is the first and only baby monitor to earn an SGS Cybersecurity Mark, a global certification that recognizes the highest standards in international cybersecurity and privacy. Dream Sight was tested by Brightsight, an SGS company and global leader in cybersecurity evaluations. For parents, this independent recognition provides extra reassurance that Owlet delivers trusted digital solutions backed by strong encryption, secure data management, and advanced privacy safeguards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106669800/en/ Owlet's Dream Sight is the first and only baby monitor to earn an SGS Cybersecu
Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory30.10.2025 13:30:00 CET | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its Suzhou, China laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This achievement marks the company’s second CLIA certification in 2025, following its San Diego facility earlier this year, underscoring Crown Bioscience’s continued commitment to expanding its global network of compliant, clinical-grade laboratories. Regulated by the Centers for Medicare and Medicaid Services (CMS), CLIA certification sets the highest federal standards for laboratory accuracy, reliability, and quality. The designation affirms that Crown Bioscience’s Suzhou laboratory meets all required compliance benchmarks, providing clients with greater confidence in the biomarker data that supports their clinical development and regulatory submissions. ‘’Earning a second CLIA certification within
SLB OneSubsea Secures EPC Contracts from PTTEP for Two Deepwater Projects Offshore Malaysia30.10.2025 13:30:00 CET | Press release
Integrated subsea production systems will help unlock important oil and gas reserves Global energy technology company SLB (NYSE: SLB) announced today the award of two sizeable engineering, procurement, and construction (EPC) contracts by PTT Exploration and Production Public Company Limited (PTTEP) to its OneSubsea™ joint venture. The contracts build on a 20-year collaboration between the two companies and cover the expansion of two fields offshore Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030090404/en/ As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block H and the Kikeh field, Malaysia’s first deepwater oil project. As part of the EPC contracts, SLB OneSubsea will deliver comprehensive subsea production systems (SPS) for the Alum, Bemban, and Permai deepwater gas fields located in Block
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
